Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ORIC Pharmaceuticals, Inc. (ORIC)
USD10.96
+0.41 (+3.89%)
US NASDAQ Healthcare Biotechnology
Address
240 East Grand Avenue 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Jacob Chacko
Website
oricpharma.com
IPO
2020-04-24
CIK 1796280 ISIN US68622P1093
Description
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD10.96
+0.41 (+3.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.01
Float Shares
47.22M
Free Float %
47.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.78% | -2.11% | -13.00% | -13.77% | -29.25% | +7.95% | +63.22% | +72.63% | -63.45% | -65.74% | -65.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
10.96
Low
15.00
+36.9%
Consensus
21.75
+98.4%
Median
23.50
+114.4%
High
25.00
+128.1%
DCF (Unlevered)
0.35
-96.8%
DCF (Levered)
0.39
-96.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
93% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 12 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
20.00
+82.5%
|
| Last Year | 6 |
21.33
+94.6%
|
| All Time | 12 |
18.75
+71.1%
|
Quality scores
Altman Z-Score
24.03
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+19.7% Q1'26: +19.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-113.2% Q1'26: -118.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+25.9% Q1'26: +48.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 11 EPS Ana. |
Dec 2027 11 Rev. Ana. 10 EPS Ana. |
Dec 2028 4 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
8.22M
8.22M – 8.22M
|
2.21M
2.21M – 2.21M
-73.1% YoY
|
10.83M
10.83M – 10.83M
+389.7% YoY
|
73.16M
73.16M – 73.16M
+575.4% YoY
|
259.28M
259.28M – 259.28M
+254.4% YoY
|
| EBITDA |
-126.74M
|
-128.25M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-127.85M
|
-129.47M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-127.85M
est: -129.13M (+1.0%)
|
-129.47M
est: -135.21M (+4.2%)
|
-127.79M
-139.82M – -115.77M
+5.5% YoY
|
-132.29M
-156.22M – -108.36M
-3.5% YoY
|
-139.60M
-161.94M – -117.27M
-5.5% YoY
|
-153.20M
-153.20M – -153.20M
-9.7% YoY
|
-38.92M
-38.92M – -38.92M
+74.6% YoY
|
| SGA |
28.82M
|
33.19M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.83
est: -1.85 (+1.2%)
|
-1.47
est: -1.52 (+3.1%)
|
-1.45
-1.59 – -1.32
+4.4% YoY
|
-1.54
-1.78 – -1.23
-6.4% YoY
|
-1.62
-1.84 – -1.34
-4.9% YoY
|
-1.75
-1.75 – -1.75
-7.8% YoY
|
-0.44
-0.44 – -0.44
+74.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | Citigroup | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
24
Total invested
13.70M
Insider transactions (90d)
0
Beneficial owners (>5%)
45
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PFIZER INC. | 5.38M | 12.00% | 5.38M | — | 5.38M | — | CO | Delaware | 2022-12-29 | ↗ |
| 2 | (1) BlackRock, Inc. | 5.10M | 7.20% | 4.94M | — | 5.10M | — | HC | Delaware | 2024-11-08 | ↗ |
| 3 | Koh, Bong | 4.43M | 6.60% | — | 4.43M | — | — | IN | United States | 2024-02-01 | ↗ |
| 4 | Shah, Nimish | 4.43M | 6.60% | — | 4.43M | — | — | IN | United States | 2024-02-01 | ↗ |
| 5 | VHCP Co-Investment Holdings III, LLC | 4.43M | 6.60% | — | 4.43M | — | — | OO | United States | 2024-02-01 | ↗ |
| 6 | VHCP Management EG, LLC | 4.43M | 6.60% | — | 4.43M | — | — | OO | United States | 2024-02-01 | ↗ |
| 7 | VHCP Management III, LLC | 4.43M | 6.60% | — | 4.43M | — | — | OO | United States | 2024-02-01 | ↗ |
| 8 | Venrock Healthcare Capital Partners EG, L.P. | 4.43M | 6.60% | — | 4.43M | — | — | PN | United States | 2024-02-01 | ↗ |
| 9 | Venrock Healthcare Capital Partners III, L.P. | 4.43M | 6.60% | — | 4.43M | — | — | PN | United States | 2024-02-01 | ↗ |
| 10 | Costas Constantinides | 4.29M | 7.90% | — | 4.29M | — | — | IN | Switzerland | 2023-07-07 | ↗ |
| 11 | Ian Charoub | 4.29M | 7.90% | — | 4.29M | — | — | IN | Switzerland | 2023-07-07 | ↗ |
| 12 | Nextech Crossover I GP S.á r.l. | 4.29M | 7.90% | 4.29M | — | 4.29M | — | OO | Switzerland | 2023-07-07 | ↗ |
| 13 | Nextech Crossover I SCSp | 4.29M | 7.90% | 4.29M | — | 4.29M | — | PN | Switzerland | 2023-07-07 | ↗ |
| 14 | Rocco Sgobbo | 4.29M | 7.90% | — | 4.29M | — | — | IN | Switzerland | 2023-07-07 | ↗ |
| 15 | James N. Topper | 4.14M | 6.20% | — | 4.14M | — | 4.14M | IN | Delaware | 2024-01-25 | ↗ |
| 16 | Patrick J. Heron | 4.14M | 6.20% | — | 4.14M | — | 4.14M | IN | Delaware | 2024-01-25 | ↗ |
| 17 | Viking Global Investors LP | 4.00M | 5.90% | — | 4.00M | — | 4.00M | — | Delaware | 2024-01-30 | ↗ |
| 18 | Peter Svennilson | 3.67M | 9.30% | 103.3K | 3.57M | 103.3K | 3.57M | IN | — | 2022-02-11 | ↗ |
| 19 | David Goeddel | 3.65M | 9.30% | 86.7K | 3.57M | 86.7K | 3.57M | IN | — | 2022-02-11 | ↗ |
| 20 | The Column Group II GP, LP | 3.57M | 9.10% | — | 3.57M | — | 3.57M | PN | — | 2022-02-11 | ↗ |
| 21 | The Column Group II, LP | 3.57M | 9.10% | — | 3.57M | — | 3.57M | PN | — | 2022-02-11 | ↗ |
| 22 | Albert Cha | 3.00M | 4.50% | — | 3.00M | — | 3.00M | IN | Delaware | 2024-01-25 | ↗ |
| 23 | James Brush | 3.00M | 4.50% | — | 3.00M | — | 3.00M | IN | Delaware | 2024-01-25 | ↗ |
| 24 | Israel A. Englander | 2.43M | 5.40% | — | 2.43M | — | 2.43M | IN | — | 2023-01-20 | ↗ |
| 25 | Millennium Group Management LLC | 2.43M | 5.40% | — | 2.43M | — | 2.43M | OO | — | 2023-01-20 | ↗ |
| 26 | Millennium Management LLC | 2.43M | 5.40% | — | 2.43M | — | 2.43M | OO | — | 2023-01-20 | ↗ |
| 27 | Victory Capital Management Inc. | 2.30M | 5.84% | 2.30M | — | 2.30M | — | IA | New York | 2022-02-02 | ↗ |
| 28 | Prosight Management, LP | 2.28M | 5.10% | — | 2.28M | — | 2.28M | IA | Delaware | 2023-06-12 | ↗ |
| 29 | Prosight Partners, LLC | 2.28M | 5.10% | — | 2.28M | — | 2.28M | OO | Delaware | 2023-06-12 | ↗ |
| 30 | W. Lawrence Hawkins | 2.28M | 5.10% | — | 2.28M | — | 2.28M | HC, IN | Delaware | 2023-06-12 | ↗ |
| 31 | FHMLSP, L.L.C. | 1.78M | 2.70% | — | 1.78M | — | 1.78M | OO | Delaware | 2024-01-25 | ↗ |
| 32 | FHMLSP, L.P. | 1.78M | 2.70% | — | 1.78M | — | 1.78M | PN | Delaware | 2024-01-25 | ↗ |
| 33 | Frazier Life Sciences Public Fund, L.P. | 1.78M | 2.70% | — | 1.78M | — | 1.78M | PN | Delaware | 2024-01-25 | ↗ |
| 34 | FHMLSP Overage, L.L.C. | 1.22M | 1.80% | — | 1.22M | — | 1.22M | OO | Delaware | 2024-01-25 | ↗ |
| 35 | FHMLSP Overage, L.P. | 1.22M | 1.80% | — | 1.22M | — | 1.22M | PN | Delaware | 2024-01-25 | ↗ |
| 36 | Frazier Life Sciences Public Overage Fund, L.P. | 1.22M | 1.80% | — | 1.22M | — | 1.22M | PN | Delaware | 2024-01-25 | ↗ |
| 37 | Daniel Estes | 759.9K | 1.10% | — | 759.9K | — | 759.9K | IN | Delaware | 2024-01-25 | ↗ |
| 38 | FHMLS XI, L.L.C. | 759.9K | 1.10% | — | 759.9K | — | 759.9K | OO | Delaware | 2024-01-25 | ↗ |
| 39 | FHMLS XI, L.P. | 759.9K | 1.10% | — | 759.9K | — | 759.9K | PN | Delaware | 2024-01-25 | ↗ |
| 40 | Frazier Life Sciences XI, L.P. | 759.9K | 1.10% | — | 759.9K | — | 759.9K | PN | Delaware | 2024-01-25 | ↗ |
| 41 | Prosight Plus Fund, LP | 604.9K | 1.30% | — | 604.9K | — | 604.9K | PN | Delaware | 2023-06-12 | ↗ |
| 42 | FHMLS X, L.L.C. | 380.4K | 0.60% | — | 380.4K | — | 380.4K | OO | Delaware | 2024-01-25 | ↗ |
| 43 | FHMLS X, L.P. | 380.4K | 0.60% | — | 380.4K | — | 380.4K | PN | Delaware | 2024-01-25 | ↗ |
| 44 | Frazier Life Sciences X, L.P. | 380.4K | 0.60% | — | 380.4K | — | 380.4K | PN | Delaware | 2024-01-25 | ↗ |
| 45 | Prosight Fund, LP | 230.8K | 0.50% | — | 230.8K | — | 230.8K | PN | Delaware | 2023-06-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
24
-142 vs prev Q
New positions
5
Closed positions
146
Increased
14
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 32.0K +32.0K (+100.0%) | 262.05M +262.1M (+100.0%) | 0.03% +0.032 pp | 0.10% +0.103 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 2 | NEXTECH INVEST, LTD. | 7.16M +— (+0.0%) | 58.59M -27.4M (-31.8%) | 7.24% -1.930 pp | 5.66% -7.419 pp | USD6.78 +20.6% | 4 qtrs — |
| 3 | ECOR1 CAPITAL, LLC | 6.73M +— (+0.0%) | 55.04M -25.7M (-31.8%) | 6.80% -1.813 pp | 2.50% -1.377 pp | USD16.89 -51.6% | 23 qtrs — |
| 4 | VIKING GLOBAL INVESTORS LP | 6.57M -9.0 (0.0%) | 53.76M -25.1M (-31.8%) | 6.64% -1.771 pp | 0.14% -0.062 pp | USD10.22 -20.0% | 8 qtrs — |
| 5 | BLACKROCK, INC. | 5.88M +598.4K (+11.3%) | 48.06M -15.3M (-24.1%) | 5.94% -0.817 pp | 0.00% 0.000 pp | USD10.20 -19.8% | 6 qtrs — |
| 6 | VR ADVISER, LLC | 5.68M -920.7K (-14.0%) | 46.43M -32.7M (-41.3%) | 5.74% -2.708 pp | 2.29% -2.162 pp | USD10.16 -19.5% | 11 qtrs — |
| 7 | PFIZER INC | 5.38M +— (+0.0%) | 43.98M -20.5M (-31.8%) | 5.43% -1.448 pp | 18.60% +3.850 pp | USD8.07 +1.4% | 5 qtrs — |
| 8 | SR ONE CAPITAL MANAGEMENT, LP | 4.51M +— (+0.0%) | 37.75M -16.4M (-30.3%) | 4.56% -1.216 pp | 5.34% -2.491 pp | USD10.15 -19.4% | 3 qtrs — |
| 9 | VANGUARD GROUP INC | 4.54M -108.2K (-2.3%) | 37.15M -18.6M (-33.4%) | 4.59% -1.362 pp | 0.00% 0.000 pp | USD14.41 -43.2% | 23 qtrs — |
| 10 | ALKEON CAPITAL MANAGEMENT LLC | 4.50M +— (+0.0%) | 36.84M -17.2M (-31.8%) | 4.55% -1.213 pp | 0.06% -0.021 pp | USD13.11 -37.6% | 22 qtrs — |
| 11 | STATE STREET CORP | 4.26M +1.9M (+77.1%) | 34.83M +6.0M (+20.8%) | 4.30% +1.226 pp | 0.00% +0.000 pp | USD9.53 -14.2% | 23 qtrs — |
| 12 | NEA MANAGEMENT COMPANY, LLC | 4.12M +— (+0.0%) | 33.69M -15.7M (-31.8%) | 4.16% -1.110 pp | 1.72% -0.994 pp | USD10.43 -21.6% | 8 qtrs — |
| 13 | ORBIMED ADVISORS LLC | 3.64M +— (+0.0%) | 29.79M -13.9M (-31.8%) | 3.68% -0.981 pp | 0.61% -0.420 pp | USD10.66 -23.3% | 4 qtrs — |
| 14 | COLUMN GROUP LLC | 3.54M +— (+0.0%) | 28.96M -13.5M (-31.8%) | 3.58% -0.954 pp | 34.98% -17.500 pp | USD33.85 -75.8% | 21 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.30M +423.8K (+14.8%) | 26.96M -7.5M (-21.8%) | 3.33% -0.345 pp | 0.00% -0.001 pp | USD10.23 -20.0% | 17 qtrs — |
| 16 | POINT72 ASSET MANAGEMENT, L.P. | 2.92M +303.2K (+11.6%) | 23.91M -7.5M (-23.9%) | 2.95% -0.399 pp | 0.03% -0.026 pp | USD9.95 -17.8% | 3 qtrs — |
| 17 | FMR LLC | 2.48M -49.1K (-1.9%) | 20.28M -10.1M (-33.2%) | 2.51% -0.731 pp | 0.00% -0.001 pp | USD19.32 -57.7% | 23 qtrs — |
| 18 | CITADEL ADVISORS LLC | 2.43M +1.2M (+103.2%) | 19.92M +5.5M (+38.5%) | 2.46% +0.927 pp | 0.00% +0.001 pp | USD8.36 -2.2% | 6 qtrs — |
| 19 | PARADIGM BIOCAPITAL ADVISORS LP | 2.40M +2.4M (+100.0%) | 19.64M +19.6M (+100.0%) | 2.43% +2.427 pp | 0.50% +0.501 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 20 | VIVO CAPITAL, LLC | 2.12M -1.0M (-32.2%) | 17.33M -20.2M (-53.8%) | 2.14% -1.861 pp | 1.12% -1.899 pp | USD7.60 +7.6% | 10 qtrs — |
| 21 | FIRST TURN MANAGEMENT, LLC | 2.01M -149.2K (-6.9%) | 16.44M -9.5M (-36.5%) | 2.03% -0.733 pp | 1.88% -2.012 pp | USD9.95 -17.8% | 8 qtrs — |
| 22 | GOLDMAN SACHS GROUP INC | 1.94M +1.0M (+114.3%) | 15.86M +5.0M (+46.1%) | 1.96% +0.802 pp | 0.00% +0.001 pp | USD9.37 -12.7% | 23 qtrs — |
| 23 | BIOIMPACT CAPITAL LLC | 1.80M +69.3K (+4.0%) | 14.71M -6.0M (-29.1%) | 1.82% -0.396 pp | 1.68% -1.714 pp | USD6.52 +25.5% | 4 qtrs — |
| 24 | GEODE CAPITAL MANAGEMENT, LLC | 1.75M +120.0K (+7.4%) | 14.32M -5.3M (-26.8%) | 1.77% -0.318 pp | 0.00% 0.000 pp | USD11.73 -30.3% | 23 qtrs — |
| 25 | ROYCE & ASSOCIATES LP | 1.51M +48.8K (+3.3%) | 12.33M -5.2M (-29.6%) | 1.52% -0.344 pp | 0.13% -0.050 pp | USD11.59 -29.4% | 3 qtrs — |
| 26 | DIMENSIONAL FUND ADVISORS LP | 1.23M +433.4K (+54.6%) | 10.04M +514.7K (+5.4%) | 1.24% +0.224 pp | 0.00% +0.000 pp | USD9.00 -9.1% | 12 qtrs — |
| 27 | FRANKLIN RESOURCES INC | 1.21M +31.2K (+2.6%) | 9.92M -4.3M (-30.0%) | 1.23% -0.287 pp | 0.00% -0.001 pp | USD7.54 +8.5% | 11 qtrs — |
| 28 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.21M +1.2M (+100.0%) | 9.86M +9.9M (+100.0%) | 1.22% +1.218 pp | 0.01% +0.010 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 29 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.20M +300.0K (+33.3%) | 9.82M -984.0K (-9.1%) | 1.21% +0.061 pp | 0.49% -0.243 pp | USD9.66 -15.3% | 3 qtrs — |
| 30 | MORGAN STANLEY | 1.19M +448.5K (+60.2%) | 9.77M +821.2K (+9.2%) | 1.21% +0.252 pp | 0.00% +0.000 pp | USD9.72 -15.8% | 23 qtrs — |
| 31 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.12M -832.2K (-42.7%) | 9.13M -14.3M (-60.9%) | 1.13% -1.366 pp | 1.27% -1.885 pp | USD5.82 +40.5% | 15 qtrs — |
| 32 | ARROWMARK COLORADO HOLDINGS LLC | 1.06M -33.7K (-3.1%) | 8.70M -4.5M (-33.9%) | 1.08% -0.330 pp | 0.19% -0.053 pp | USD9.74 -16.0% | 23 qtrs — |
| 33 | SIREN, L.L.C. | 1.01M +— (+0.0%) | 8.24M -3.8M (-31.8%) | 1.02% -0.271 pp | 0.25% -0.227 pp | USD10.25 -20.2% | 6 qtrs — |
| 34 | SPHERA FUNDS MANAGEMENT LTD. | 1.00M +572.7K (+132.7%) | 8.22M +3.0M (+58.6%) | 1.02% +0.462 pp | 1.59% +0.496 pp | USD8.85 -7.6% | 6 qtrs — |
| 35 | EUCLIDEAN CAPITAL LLC | 989.4K +— (+0.0%) | 8.09M -3.8M (-31.8%) | 1.00% -0.267 pp | 2.19% -2.798 pp | USD27.05 -69.8% | 21 qtrs — |
| 36 | EVENTIDE ASSET MANAGEMENT, LLC | 952.4K +864.0 (+0.1%) | 7.79M -3.6M (-31.8%) | 0.96% -0.256 pp | 0.12% -0.066 pp | USD10.15 -19.4% | 3 qtrs — |
| 37 | BALYASNY ASSET MANAGEMENT L.P. | 950.2K -569.1K (-37.5%) | 7.77M -10.5M (-57.4%) | 0.96% -0.984 pp | 0.01% -0.013 pp | USD8.74 -6.4% | 6 qtrs — |
| 38 | NORTHERN TRUST CORP | 885.5K -3.1K (-0.3%) | 7.24M -3.4M (-32.1%) | 0.89% -0.243 pp | 0.00% 0.000 pp | USD11.73 -30.3% | 23 qtrs — |
| 39 | UBS GROUP AG | 734.9K +395.6K (+116.6%) | 6.01M +1.9M (+47.7%) | 0.74% +0.308 pp | 0.00% +0.000 pp | USD9.74 -16.0% | 23 qtrs — |
| 40 | BARCLAYS PLC | 718.5K +611.3K (+569.9%) | 5.88M +4.8M (+434.6%) | 0.73% +0.589 pp | 0.00% +0.001 pp | USD8.39 -2.5% | 11 qtrs — |
| 41 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 621.1K +17.9K (+3.0%) | 5.08M -2.2M (-29.8%) | 0.63% -0.144 pp | 0.00% 0.000 pp | USD10.64 -23.1% | 23 qtrs — |
| 42 | RENAISSANCE TECHNOLOGIES LLC | 572.7K +558.2K (+3,849.8%) | 4.68M +4.5M (+2,592.5%) | 0.58% +0.560 pp | 0.01% +0.007 pp | USD8.24 -0.7% | 3 qtrs — |
| 43 | LORD, ABBETT & CO. LLC | 564.3K +564.3K (+100.0%) | 4.62M +4.6M (+100.0%) | 0.57% +0.570 pp | 0.01% +0.014 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 44 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 549.0K +101.6K (+22.7%) | 4.49M -877.6K (-16.3%) | 0.55% -0.018 pp | 0.01% -0.002 pp | USD10.06 -18.7% | 8 qtrs — |
| 45 | BLUE OWL CAPITAL HOLDINGS LP | 515.0K +515.0K (+100.0%) | 4.21M +4.2M (+100.0%) | 0.52% +0.520 pp | 0.32% +0.315 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 46 | BANK OF AMERICA CORP /DE/ | 507.5K +404.1K (+390.6%) | 4.15M +2.9M (+234.4%) | 0.51% +0.381 pp | 0.00% +0.000 pp | USD8.04 +1.7% | 23 qtrs — |
| 47 | POLAR CAPITAL HOLDINGS PLC | 502.4K +33.8K (+7.2%) | 4.11M -1.5M (-26.9%) | 0.51% -0.092 pp | 0.02% -0.011 pp | USD11.74 -30.3% | 2 qtrs — |
| 48 | LOGOS GLOBAL MANAGEMENT LP | 450.0K +450.0K (+100.0%) | 3.68M +3.7M (+100.0%) | 0.45% +0.455 pp | 0.22% +0.222 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 49 | REDMILE GROUP, LLC | 448.1K +448.1K (+100.0%) | 3.67M +3.7M (+100.0%) | 0.45% +0.453 pp | 0.27% +0.270 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 50 | JPMORGAN CHASE & CO | 414.8K -813.7K (-66.2%) | 3.39M -11.3M (-77.0%) | 0.42% -1.153 pp | 0.00% -0.001 pp | USD10.10 -19.0% | 23 qtrs — |
| 51 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 350.9K +334.4K (+2,034.7%) | 2.87M +2.7M (+1,355.2%) | 0.35% +0.334 pp | 0.01% +0.007 pp | USD8.36 -2.2% | 2 qtrs — |
| 52 | Y-INTERCEPT (HONG KONG) LTD | 341.4K +341.4K (+100.0%) | 2.79M +2.8M (+100.0%) | 0.35% +0.345 pp | 0.06% +0.063 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 53 | VICTORY CAPITAL MANAGEMENT INC | 332.8K +200.5K (+151.7%) | 2.72M +1.1M (+71.6%) | 0.34% +0.167 pp | 0.00% +0.001 pp | USD7.27 +12.5% | 23 qtrs — |
| 54 | ATOM INVESTORS LP | 290.0K +147.4K (+103.3%) | 2.37M +660.7K (+38.6%) | 0.29% +0.111 pp | 0.19% +0.059 pp | USD7.65 +6.9% | 15 qtrs — |
| 55 | SUPERSTRING CAPITAL MANAGEMENT LP | 255.4K +166.0K (+185.8%) | 2.09M +1.0M (+94.8%) | 0.26% +0.144 pp | 1.12% +0.062 pp | USD8.60 -4.9% | 6 qtrs — |
| 56 | WOODLINE PARTNERS LP | 246.5K +— (+0.0%) | 2.02M -941.8K (-31.8%) | 0.25% -0.066 pp | 0.01% -0.006 pp | USD10.17 -19.6% | 3 qtrs — |
| 57 | JANE STREET GROUP, LLC | 244.0K +181.4K (+289.3%) | 2.00M +1.2M (+165.4%) | 0.25% +0.166 pp | 0.00% +0.000 pp | USD8.22 -0.5% | 12 qtrs — |
| 58 | SQUAREPOINT OPS LLC | 229.4K +198.7K (+646.4%) | 1.88M +1.5M (+408.8%) | 0.23% +0.193 pp | 0.00% +0.002 pp | USD8.44 -3.1% | 3 qtrs — |
| 59 | BOOTHBAY FUND MANAGEMENT, LLC | 218.6K +107.8K (+97.2%) | 1.79M +458.2K (+34.5%) | 0.22% +0.079 pp | 0.03% +0.007 pp | USD10.12 -19.2% | 2 qtrs — |
| 60 | RUSSELL INVESTMENTS GROUP, LTD. | 207.0K +202.1K (+4,062.4%) | 1.69M +1.6M (+2,737.4%) | 0.21% +0.203 pp | 0.00% +0.002 pp | USD8.27 -1.1% | 2 qtrs — |
| 61 | WELLINGTON MANAGEMENT GROUP LLP | 191.8K +41.2K (+27.4%) | 1.57M -238.0K (-13.2%) | 0.19% +0.001 pp | 0.00% +0.000 pp | USD9.71 -15.8% | 9 qtrs — |
| 62 | BANK OF NEW YORK MELLON CORP | 187.9K +12.2K (+6.9%) | 1.54M -571.4K (-27.1%) | 0.19% -0.035 pp | 0.00% 0.000 pp | USD9.76 -16.2% | 23 qtrs — |
| 63 | RAFFERTY ASSET MANAGEMENT, LLC | 177.2K +91.6K (+107.0%) | 1.45M +422.2K (+41.1%) | 0.18% +0.070 pp | 0.01% +0.002 pp | USD9.62 -15.0% | 8 qtrs — |
| 64 | AQR CAPITAL MANAGEMENT LLC | 174.3K +2.4K (+1.4%) | 1.43M -637.5K (-30.9%) | 0.18% -0.044 pp | 0.00% -0.001 pp | USD8.83 -7.4% | 4 qtrs — |
| 65 | HENNION & WALSH ASSET MANAGEMENT, INC. | 170.1K +23.0K (+15.7%) | 1.39M -373.4K (-21.2%) | 0.17% -0.016 pp | 0.05% -0.016 pp | USD8.26 -1.0% | 7 qtrs — |
| 66 | TD ASSET MANAGEMENT INC | 169.8K +18.1K (+12.0%) | 1.39M -431.2K (-23.7%) | 0.17% -0.023 pp | 0.00% 0.000 pp | USD10.67 -23.3% | 9 qtrs — |
| 67 | CITIGROUP INC | 154.1K +143.5K (+1,349.6%) | 1.26M +1.1M (+888.1%) | 0.16% +0.142 pp | 0.00% +0.001 pp | USD8.23 -0.6% | 23 qtrs — |
| 68 | NUVEEN, LLC | 144.4K +6.7K (+4.9%) | 1.18M -471.1K (-28.5%) | 0.15% -0.030 pp | 0.00% 0.000 pp | USD6.37 +28.4% | 4 qtrs — |
| 69 | DAFNA CAPITAL MANAGEMENT LLC | 141.0K +36.4K (+34.8%) | 1.15M -102.3K (-8.1%) | 0.14% +0.009 pp | 0.27% -0.042 pp | USD6.25 +30.9% | 4 qtrs — |
| 70 | AMERICAN CENTURY COMPANIES INC | 134.9K +4.4K (+3.3%) | 1.10M -463.2K (-29.6%) | 0.14% -0.031 pp | 0.00% 0.000 pp | USD9.93 -17.6% | 11 qtrs — |
| 71 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 128.6K +2.0K (+1.6%) | 1.04M -478.4K (-31.5%) | 0.13% -0.032 pp | 0.00% 0.000 pp | USD10.99 -25.6% | 11 qtrs — |
| 72 | STATE OF WISCONSIN INVESTMENT BOARD | 124.3K +34.6K (+38.5%) | 1.02M -59.9K (-5.6%) | 0.13% +0.011 pp | 0.00% 0.000 pp | USD9.76 -16.2% | 7 qtrs — |
| 73 | XTX TOPCO LTD | 110.6K +110.6K (+100.0%) | 904.4K +904.4K (+100.0%) | 0.11% +0.112 pp | 0.02% +0.024 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 74 | INVESCO LTD. | 109.7K +18.1K (+19.8%) | 897.7K -201.7K (-18.3%) | 0.11% -0.006 pp | 0.00% +0.000 pp | USD9.41 -13.1% | 11 qtrs — |
| 75 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 108.8K +108.8K (+100.0%) | 890.3K +890.3K (+100.0%) | 0.11% +0.110 pp | 0.01% +0.007 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 76 | MILLENNIUM MANAGEMENT LLC | 97.4K -43.0K (-30.6%) | 797.0K -888.2K (-52.7%) | 0.10% -0.081 pp | 0.00% 0.000 pp | USD9.71 -15.8% | 16 qtrs — |
| 77 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 89.5K +40.4K (+82.4%) | 732.4K +143.2K (+24.3%) | 0.09% +0.028 pp | 0.01% +0.005 pp | USD9.56 -14.4% | 3 qtrs — |
| 78 | SWISS NATIONAL BANK | 86.2K +20.1K (+30.4%) | 705.1K -88.1K (-11.1%) | 0.09% +0.003 pp | 0.00% +0.000 pp | USD11.11 -26.4% | 7 qtrs — |
| 79 | WELLS FARGO & COMPANY/MN | 82.5K +31.6K (+61.9%) | 675.1K +63.6K (+10.4%) | 0.08% +0.018 pp | 0.00% +0.000 pp | USD8.95 -8.6% | 23 qtrs — |
| 80 | GRAHAM CAPITAL MANAGEMENT, L.P. | 81.6K +81.6K (+100.0%) | 667.3K +667.3K (+100.0%) | 0.08% +0.082 pp | 0.02% +0.016 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 81 | RHUMBLINE ADVISERS | 77.7K -4.3K (-5.3%) | 635.6K -348.7K (-35.4%) | 0.08% -0.027 pp | 0.00% 0.000 pp | USD8.29 -1.3% | 11 qtrs — |
| 82 | GSA CAPITAL PARTNERS LLP | 70.6K +38.7K (+121.2%) | 578.0K +195.0K (+50.9%) | 0.07% +0.031 pp | 0.05% +0.018 pp | USD9.91 -17.5% | 4 qtrs — |
| 83 | PROFUND ADVISORS LLC | 65.2K +46.4K (+248.1%) | 533.0K +308.4K (+137.3%) | 0.07% +0.042 pp | 0.02% +0.009 pp | USD9.28 -11.9% | 8 qtrs — |
| 84 | ALLIANCEBERNSTEIN L.P. | 63.8K +— (+0.0%) | 522.0K -243.8K (-31.8%) | 0.06% -0.017 pp | 0.00% 0.000 pp | USD7.82 +4.6% | 9 qtrs — |
| 85 | UBS ASSET MANAGEMENT AMERICAS INC | 50.8K +27.5K (+118.6%) | 415.4K +136.6K (+49.0%) | 0.05% +0.022 pp | 0.00% +0.000 pp | USD9.93 -17.6% | 7 qtrs — |
| 86 | DEUTSCHE BANK AG\ | 44.9K +2.4K (+5.7%) | 367.6K -142.4K (-27.9%) | 0.05% -0.009 pp | 0.00% 0.000 pp | USD11.46 -28.6% | 23 qtrs — |
| 87 | QUEST PARTNERS LLC | 44.4K +28.9K (+186.4%) | 363.1K +177.1K (+95.2%) | 0.04% +0.025 pp | 0.02% +0.008 pp | USD7.86 +4.1% | 8 qtrs — |
| 88 | SG AMERICAS SECURITIES, LLC | 41.0K +23.0K (+127.6%) | 336.0K +120.0K (+55.6%) | 0.04% +0.018 pp | 0.00% 0.000 pp | USD9.86 -17.0% | 6 qtrs — |
| 89 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 41.1K +9.7K (+30.9%) | 334.8K -40.0K (-10.7%) | 0.04% +0.001 pp | 0.00% 0.000 pp | USD8.69 -5.9% | 7 qtrs — |
| 90 | ALGERT GLOBAL LLC | 40.5K +40.5K (+100.0%) | 331.0K +331.0K (+100.0%) | 0.04% +0.041 pp | 0.01% +0.005 pp | USD8.18 +0.0% | 1 qtrs NEW |
| 91 | BNP PARIBAS ARBITRAGE, SNC | 40.1K -198.5K (-83.2%) | 328.1K -2.5M (-88.5%) | 0.04% -0.265 pp | 0.00% -0.001 pp | USD11.26 -27.4% | 5 qtrs — |
| 92 | OPTIMIZE FINANCIAL INC | 39.6K +568.0 (+1.5%) | 324.0K -144.5K (-30.8%) | 0.04% -0.010 pp | 0.16% -0.081 pp | USD11.95 -31.5% | 2 qtrs — |
| 93 | LMR PARTNERS LLP | 35.3K +— (+0.0%) | 288.5K -134.7K (-31.8%) | 0.04% -0.010 pp | 0.00% -0.001 pp | USD5.58 +46.6% | 4 qtrs — |
| 94 | METLIFE INVESTMENT MANAGEMENT, LLC | 34.0K +— (+0.0%) | 277.9K -129.8K (-31.8%) | 0.03% -0.009 pp | 0.00% -0.001 pp | USD8.62 -5.1% | 11 qtrs — |
| 95 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 34.0K +1.3K (+3.9%) | 277.8K -114.5K (-29.2%) | 0.03% -0.008 pp | 0.00% 0.000 pp | USD11.50 -28.9% | 11 qtrs — |
| 96 | LEGAL & GENERAL GROUP PLC | 33.8K +713.0 (+2.2%) | 276.8K -120.7K (-30.4%) | 0.03% -0.008 pp | 0.00% +0.000 pp | USD11.37 -28.1% | 11 qtrs — |
| 97 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 31.5K +31.5K (+100.0%) | 257.7K +257.7K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD8.18 +0.0% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 97 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.81% | 464.8K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.33% | 118.3K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.33% | 35.52M | 0.35% |
| 4 | Tema Oncology ETF CANC | 0.33% | 465.1K | 0.75% |
| 5 | Optimize Strategy Index ETF OPTZ | 0.23% | 551.9K | 0.25% |
| 6 | iShares Micro-Cap ETF IWC | 0.18% | 2.72M | 0.60% |
| 7 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.11% | 3.06M | 0.55% |
| 8 | T. Rowe Price Innovation Leaders ETF TNXT | 0.08% | 15.0K | 0.49% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.08% | 357.6K | 0.40% |
| 10 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.08% | 57.7K | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.00
Bullish
Ratio by volume
3.00
Bullish
Buys
12
Sells
4
Shares acquired
1.53M
Shares disposed
110.7K
Cash buys
—
Cash sales
3.00
Net activity
+1,419,300
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-24 | Piscitelli Dominic | Officer | M-Exempt | D | Stock Option (right to buy) | 52,000 | 4.36 | 226.7K | 144,500 | D | ↗ |
| 2026-01-16 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 3,200 | 12.00 | 38.4K | 213,072 | I | ↗ |
| 2026-01-02 | You Angie | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 8.17 | 326.8K | 40,000 | D | ↗ |
| 2026-01-02 | Piscitelli Dominic | Officer | A-Award | A | Stock Option (right to buy) | 206,500 | 8.17 | 1.69M | 206,500 | D | ↗ |
| 2026-01-02 | Multani Pratik S | Officer | A-Award | A | Restricted Stock Unit | 35,500 | 0.00 | — | 35,500 | D | ↗ |
| 2026-01-02 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 8.17 | 326.8K | 40,000 | D | ↗ |
| 2026-01-02 | Hoerter Steven L. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 8.17 | 326.8K | 40,000 | D | ↗ |
| 2026-01-02 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 8.17 | 326.8K | 40,000 | D | ↗ |
| 2026-01-02 | Dier Mardi | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 8.17 | 326.8K | 40,000 | D | ↗ |
| 2026-01-02 | Chacko Jacob | Director / Officer | A-Award | A | Restricted Stock Unit | 112,500 | 0.00 | — | 112,500 | D | ↗ |
| 2025-12-16 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 10,720 | 9.06 | 97.1K | 68,148 | D | ↗ |
| 2025-12-16 | Multani Pratik S | Officer | S-Sale | D | Common Stock | 10,720 | 9.06 | 97.1K | 68,149 | D | ↗ |
| 2025-12-16 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 33,374 | 9.06 | 302.4K | 581,711 | D | ↗ |
| 2025-12-15 | Piscitelli Dominic | Officer | M-Exempt | D | Restricted Stock Unit | 10,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-12-15 | Multani Pratik S | Officer | M-Exempt | D | Restricted Stock Unit | 8,000 | 0.00 | — | 0 | D | ↗ |
| 2025-12-15 | Chacko Jacob | Director / Officer | M-Exempt | D | Restricted Stock Unit | 22,000 | 0.00 | — | 0 | D | ↗ |
| 2025-12-08 | Kunkel Lori Anne | Director | M-Exempt | A | Common Stock | 10,000 | 7.90 | 79.0K | 84,200 | D | ↗ |
| 2025-12-04 | Kunkel Lori Anne | Director | M-Exempt | A | Common Stock | 5,534 | 3.75 | 20.8K | 74,200 | D | ↗ |
| 2025-10-06 | Piscitelli Dominic | Officer | M-Exempt | D | Stock Option (right to buy) | 11,000 | 4.36 | 48.0K | 196,500 | D | ↗ |
| 2025-10-06 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 37,461 | 12.32 | 461.5K | 531,419 | D | ↗ |
| 2025-10-03 | Heyman Richard A. | Director | M-Exempt | D | Stock Option (right to buy) | 18,125 | 1.60 | 29.0K | 0 | D | ↗ |
| 2025-10-01 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 53,001 | 12.05 | 638.8K | 568,880 | D | ↗ |
| 2025-09-30 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 34,538 | 12.01 | 414.7K | 621,881 | D | ↗ |
| 2025-09-22 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 125,000 | 10.80 | 1.35M | 656,419 | D | ↗ |
| 2025-07-01 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 20,000 | 10.05 | 201.0K | 48,317 | D | ↗ |
| 2025-06-24 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 32,466 | 10.50 | 341.0K | 68,317 | D | ↗ |
| 2025-06-23 | You Angie | Director | P-Purchase | A | Common Stock | 1,403 | 9.43 | 13.2K | 28,000 | D | ↗ |
| 2025-06-23 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 584 | 10.00 | 5.8K | 101,233 | D | ↗ |
| 2025-06-20 | You Angie | Director | P-Purchase | A | Common Stock | 26,597 | 9.39 | 249.7K | 26,597 | D | ↗ |
| 2025-06-12 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 300 | 10.00 | 3.0K | 101,817 | D | ↗ |
| 2025-06-11 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 1,276 | 10.00 | 12.8K | 103,817 | D | ↗ |
| 2025-06-10 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 324 | 10.00 | 3.2K | 105,093 | D | ↗ |
| 2025-06-09 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 300 | 10.00 | 3.0K | 103,864 | D | ↗ |
| 2025-06-06 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 2,600 | 10.01 | 26.0K | 104,164 | D | ↗ |
| 2025-03-03 | Kunkel Lori Anne | Director | M-Exempt | A | Common Stock | 20,500 | 6.33 | 129.8K | 68,666 | D | ↗ |
| 2025-01-02 | You Angie | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 8.26 | 289.1K | 35,000 | D | ↗ |
| 2025-01-02 | Piscitelli Dominic | Officer | A-Award | A | Restricted Stock Unit | 34,000 | 0.00 | — | 34,000 | D | ↗ |
| 2025-01-02 | Multani Pratik S | Officer | A-Award | A | Stock Option (right to buy) | 202,500 | 8.26 | 1.67M | 202,500 | D | ↗ |
| 2025-01-02 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 8.26 | 289.1K | 35,000 | D | ↗ |
| 2025-01-02 | Hoerter Steven L. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 8.26 | 289.1K | 35,000 | D | ↗ |
| 2025-01-02 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 8.26 | 289.1K | 35,000 | D | ↗ |
| 2025-01-02 | Dier Mardi | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 8.26 | 289.1K | 35,000 | D | ↗ |
| 2025-01-02 | Chacko Jacob | Director / Officer | A-Award | A | Restricted Stock Unit | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2024-12-16 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 8,851 | 8.28 | 73.3K | 106,764 | D | ↗ |
| 2024-12-16 | Multani Pratik S | Officer | S-Sale | D | Common Stock | 8,850 | 8.28 | 73.3K | 46,765 | D | ↗ |
| 2024-12-16 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 24,660 | 8.28 | 204.2K | 778,648 | D | ↗ |
| 2024-12-15 | Piscitelli Dominic | Officer | M-Exempt | D | Restricted Stock Unit | 6,042 | 0.00 | — | 0 | D | ↗ |
| 2024-12-15 | Multani Pratik S | Officer | M-Exempt | D | Restricted Stock Unit | 8,000 | 0.00 | — | 8,000 | D | ↗ |
| 2024-12-15 | Chacko Jacob | Director / Officer | M-Exempt | D | Restricted Stock Unit | 22,000 | 0.00 | — | 22,000 | D | ↗ |
| 2024-06-12 | You Angie | Director | A-Award | A | Stock Option (right to buy) | 25,600 | 7.90 | 202.2K | 25,600 | — | ↗ |
| 2024-06-12 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 25,600 | 7.90 | 202.2K | 25,600 | — | ↗ |
| 2024-06-12 | Hoerter Steven L. | Director | A-Award | A | Stock Option (right to buy) | 25,600 | 7.90 | 202.2K | 25,600 | — | ↗ |
| 2024-06-12 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 25,600 | 7.90 | 202.2K | 25,600 | — | ↗ |
| 2024-06-12 | Dier Mardi | Director | A-Award | A | Stock Option (right to buy) | 25,600 | 7.90 | 202.2K | 25,600 | — | ↗ |
| 2024-06-03 | Kunkel Lori Anne | Director | M-Exempt | D | Stock Option (right to buy) | 20,500 | 3.75 | 76.9K | 33,200 | — | ↗ |
| 2024-03-06 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 40,000 | 16.21 | 648.4K | 728,544 | — | ↗ |
| 2024-02-07 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 26,042 | 12.30 | 320.2K | 768,544 | — | ↗ |
| 2024-02-06 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 13,958 | 12.12 | 169.2K | 794,586 | — | ↗ |
| 2024-01-02 | Piscitelli Dominic | Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 9.14 | 1.65M | 180,000 | — | ↗ |
| 2024-01-02 | Multani Pratik S | Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 9.14 | 1.65M | 180,000 | — | ↗ |
| 2024-01-02 | Chacko Jacob | Director / Officer | A-Award | A | Stock Option (right to buy) | 510,000 | 9.14 | 4.66M | 510,000 | — | ↗ |
| 2023-12-15 | Piscitelli Dominic | Officer | S-Sale | D | Common Stock | 5,282 | 8.58 | 45.3K | 83,809 | — | ↗ |
| 2023-12-15 | Multani Pratik S | Officer | M-Exempt | D | Restricted Stock Unit | 6,042 | 0.00 | — | 6,042 | — | ↗ |
| 2023-12-15 | Chacko Jacob | Director / Officer | M-Exempt | A | Common Stock | 38,667 | 0.00 | — | 823,083 | — | ↗ |
| 2023-07-11 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 5,156 | 8.01 | 41.3K | 780,652 | — | ↗ |
| 2023-07-10 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 10,508 | 8.01 | 84.2K | 785,808 | — | ↗ |
| 2023-07-05 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 4,336 | 8.01 | 34.7K | 796,316 | — | ↗ |
| 2023-06-26 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 20,000 | 8.03 | 160.6K | 800,652 | — | ↗ |
| 2023-06-14 | You Angie | Director | A-Award | A | Stock Option (right to buy) | 20,500 | 6.33 | 129.8K | 20,500 | — | ↗ |
| 2023-06-14 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 20,500 | 6.33 | 129.8K | 20,500 | — | ↗ |
| 2023-06-14 | Hoerter Steven L. | Director | A-Award | A | Stock Option (right to buy) | 20,500 | 6.33 | 129.8K | 20,500 | — | ↗ |
| 2023-06-14 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 20,500 | 6.33 | 129.8K | 20,500 | — | ↗ |
| 2023-06-14 | Dier Mardi | Director | A-Award | A | Stock Option (right to buy) | 20,500 | 6.33 | 129.8K | 20,500 | — | ↗ |
| 2023-02-01 | Piscitelli Dominic | Officer | A-Award | A | Restricted Stock Unit | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2023-02-01 | Multani Pratik S | Officer | A-Award | A | Stock Option (right to buy) | 145,000 | 6.00 | 870.0K | 145,000 | — | ↗ |
| 2023-02-01 | Chacko Jacob | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 6.00 | 2.40M | 400,000 | — | ↗ |
| 2022-12-23 | PFIZER INC | Director | — | D | Common Stock | 0 | 0.00 | — | 5,376,344 | — | ↗ |
| 2022-12-15 | Piscitelli Dominic | Officer | M-Exempt | D | Restricted Stock Unit | 6,041 | 0.00 | — | 12,084 | — | ↗ |
| 2022-12-15 | Multani Pratik S | Officer | M-Exempt | D | Restricted Stock Unit | 6,041 | 0.00 | — | 12,084 | — | ↗ |
| 2022-12-15 | Chacko Jacob | Officer | M-Exempt | A | Common Stock | 16,666 | 0.00 | — | 822,789 | — | ↗ |
| 2022-07-20 | Piscitelli Dominic | Officer | D-Return | D | Stock Option (right to buy) | 207,500 | 6.44 | 1.34M | 0 | — | ↗ |
| 2022-07-20 | Multani Pratik S | Officer | D-Return | D | Stock Option (right to buy) | 108,750 | 0.00 | — | 0 | — | ↗ |
| 2022-07-20 | Chacko Jacob | Director / Officer | D-Return | D | Stock Option (right to buy) | 280,000 | 29.83 | 8.35M | 0 | — | ↗ |
| 2022-06-17 | You Angie | Director | A-Award | A | Stock Option (right to buy) | 45,158 | 0.00 | — | 45,158 | — | ↗ |
| 2022-06-17 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 53,700 | 0.00 | — | 53,700 | — | ↗ |
| 2022-06-17 | Hoerter Steven L. | Director | A-Award | A | Stock Option (right to buy) | 50,283 | 0.00 | — | 50,283 | — | ↗ |
| 2022-06-17 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 53,700 | 0.00 | — | 53,700 | — | ↗ |
| 2022-06-17 | Dier Mardi | Director | A-Award | A | Stock Option (right to buy) | 53,700 | 0.00 | — | 53,700 | — | ↗ |
| 2022-05-13 | Chacko Jacob | Director / Officer | P-Purchase | A | Common Stock | 76,072 | 2.82 | 214.6K | 802,652 | — | ↗ |
| 2022-05-12 | Chacko Jacob | Director / Officer | P-Purchase | A | Common Stock | 69,354 | 2.75 | 190.5K | 726,580 | — | ↗ |
| 2022-05-11 | Chacko Jacob | Officer | P-Purchase | A | Common Stock | 304,574 | 2.90 | 883.6K | 657,226 | — | ↗ |
| 2022-03-31 | Piscitelli Dominic | Officer | P-Purchase | A | Common Stock | 60,000 | 5.36 | 321.6K | 60,000 | — | ↗ |
| 2022-03-25 | Chacko Jacob | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 4.54 | 227.2K | 352,652 | — | ↗ |
| 2022-03-23 | Chacko Jacob | Director / Officer | P-Purchase | A | Common Stock | 257,127 | 4.98 | 1.28M | 259,779 | — | ↗ |
| 2022-02-01 | Piscitelli Dominic | Officer | A-Award | A | Stock Option (right to buy) | 108,750 | 9.48 | 1.03M | 108,750 | — | ↗ |
| 2022-02-01 | Multani Pratik S | Officer | A-Award | A | Restricted Stock Unit | 18,125 | 0.00 | — | 18,125 | — | ↗ |
| 2022-02-01 | Chacko Jacob | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 9.48 | 2.84M | 300,000 | — | ↗ |
| 2021-11-16 | COLUMN GROUP II, LP | 10% Owner | J-Other | A | Common Stock | 86,716 | 0.00 | — | 103,341 | — | ↗ |
| 2021-11-12 | COLUMN GROUP II, LP | 10% Owner | M-Exempt | A | Common Stock | 16,625 | 16.00 | 266.0K | 16,625 | — | ↗ |
| 2021-11-09 | You Angie | Director | A-Award | A | Stock Option (right to buy) | 33,250 | 17.42 | 579.2K | 33,250 | — | ↗ |
| 2021-09-15 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 682 | 25.03 | 17.1K | 216,272 | — | ↗ |
| 2021-09-15 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 3,736 | 25.06 | 93.6K | 2,652 | — | ↗ |
| 2021-09-14 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 706 | 25.05 | 17.7K | 216,954 | — | ↗ |
| 2021-09-14 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 4,420 | 25.05 | 110.7K | 6,388 | — | ↗ |
| 2021-09-13 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 601 | 25.01 | 15.0K | 217,660 | — | ↗ |
| 2021-09-13 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 2,801 | 25.02 | 70.1K | 10,808 | — | ↗ |
| 2021-09-10 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 479 | 25.10 | 12.0K | 218,261 | — | ↗ |
| 2021-09-10 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 2,942 | 25.08 | 73.8K | 13,609 | — | ↗ |
| 2021-09-08 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 200 | 25.04 | 5.0K | 16,551 | — | ↗ |
| 2021-09-07 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 1,086 | 25.11 | 27.3K | 218,740 | — | ↗ |
| 2021-09-07 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 5,981 | 25.11 | 150.2K | 16,751 | — | ↗ |
| 2021-08-13 | Hoerter Steven L. | Director | A-Award | A | Stock Option (right to buy) | 33,250 | 18.63 | 619.4K | 33,250 | — | ↗ |
| 2021-06-16 | Svennilson Peter | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 16,625 | 19.03 | 316.4K | 16,625 | — | ↗ |
| 2021-06-16 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 16,625 | 19.03 | 316.4K | 16,625 | — | ↗ |
| 2021-06-16 | Heyman Richard A. | Director | A-Award | A | Stock Option (right to buy) | 16,625 | 19.03 | 316.4K | 16,625 | — | ↗ |
| 2021-06-16 | GORDON CARL L | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 16,625 | 19.03 | 316.4K | 16,625 | — | ↗ |
| 2021-06-16 | Dier Mardi | Director | A-Award | A | Stock Option (right to buy) | 16,625 | 19.03 | 316.4K | 16,625 | — | ↗ |
| 2021-05-27 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 400 | 25.07 | 10.0K | 22,732 | — | ↗ |
| 2021-05-24 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 100 | 25.00 | 2.5K | 39,092 | — | ↗ |
| 2021-05-24 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 100 | 25.00 | 2.5K | 219,826 | — | ↗ |
| 2021-05-24 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 12 | 25.00 | 300.00 | 23,132 | — | ↗ |
| 2021-05-21 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 1,231 | 25.19 | 31.0K | 39,192 | — | ↗ |
| 2021-05-21 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 600 | 25.25 | 15.2K | 219,926 | — | ↗ |
| 2021-05-21 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 4,790 | 25.20 | 120.7K | 23,144 | — | ↗ |
| 2021-05-20 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 659 | 25.08 | 16.5K | 40,423 | — | ↗ |
| 2021-05-20 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 700 | 25.08 | 17.6K | 220,526 | — | ↗ |
| 2021-05-20 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 2,468 | 25.07 | 61.9K | 27,934 | — | ↗ |
| 2021-05-18 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 2,800 | 25.34 | 71.0K | 41,082 | — | ↗ |
| 2021-05-18 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 2,161 | 25.32 | 54.7K | 221,226 | — | ↗ |
| 2021-05-18 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 11,132 | 25.37 | 282.4K | 30,602 | — | ↗ |
| 2021-05-17 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 500 | 25.06 | 12.5K | 43,882 | — | ↗ |
| 2021-05-17 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 498 | 25.07 | 12.5K | 223,387 | — | ↗ |
| 2021-05-17 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 2,550 | 25.05 | 63.9K | 41,734 | — | ↗ |
| 2021-05-14 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 4,615 | 25.38 | 117.1K | 44,382 | — | ↗ |
| 2021-05-14 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 3,215 | 25.31 | 81.4K | 223,885 | — | ↗ |
| 2021-05-14 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 13,896 | 25.36 | 352.5K | 44,284 | — | ↗ |
| 2021-05-13 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 100 | 25.00 | 2.5K | 48,997 | — | ↗ |
| 2021-05-13 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 730 | 25.04 | 18.3K | 58,180 | — | ↗ |
| 2021-05-12 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 103 | 25.00 | 2.6K | 49,097 | — | ↗ |
| 2021-05-12 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 400 | 25.02 | 10.0K | 58,910 | — | ↗ |
| 2021-05-11 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 300 | 25.16 | 7.5K | 49,200 | — | ↗ |
| 2021-05-11 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 100 | 25.11 | 2.5K | 227,100 | — | ↗ |
| 2021-05-11 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 1,090 | 25.22 | 27.5K | 59,310 | — | ↗ |
| 2021-04-30 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 100 | 25.19 | 2.5K | 49,500 | — | ↗ |
| 2021-04-30 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 100 | 25.26 | 2.5K | 227,200 | — | ↗ |
| 2021-04-30 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 600 | 25.24 | 15.1K | 60,400 | — | ↗ |
| 2021-04-28 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 200 | 25.11 | 5.0K | 49,600 | — | ↗ |
| 2021-04-28 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 100 | 25.08 | 2.5K | 227,300 | — | ↗ |
| 2021-04-28 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 700 | 25.06 | 17.5K | 61,000 | — | ↗ |
| 2021-04-01 | SCHELLER RICHARD H | Director | S-Sale | D | Common Stock | 200 | 25.00 | 5.0K | 49,800 | — | ↗ |
| 2021-04-01 | Heyman Richard A. | Director | S-Sale | D | Common Stock | 100 | 25.00 | 2.5K | 227,400 | — | ↗ |
| 2021-04-01 | Chacko Jacob | Director / Officer | S-Sale | D | Common Stock | 800 | 25.09 | 20.1K | 61,700 | — | ↗ |
| 2021-03-30 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 27,869 | 23.93 | 666.9K | 2,212,571 | — | ↗ |
| 2021-03-30 | GORDON CARL L | Director | S-Sale | D | Common Stock | 27,869 | 23.93 | 666.9K | 2,212,571 | — | ↗ |
| 2021-03-29 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 75,555 | 23.31 | 1.76M | 2,240,440 | — | ↗ |
| 2021-03-29 | GORDON CARL L | Director | S-Sale | D | Common Stock | 75,555 | 23.31 | 1.76M | 2,240,440 | — | ↗ |
| 2021-03-26 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 27,816 | 23.88 | 664.2K | 2,315,995 | — | ↗ |
| 2021-03-26 | GORDON CARL L | Director | S-Sale | D | Common Stock | 27,816 | 23.88 | 664.2K | 2,315,995 | — | ↗ |
| 2021-03-25 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 51,523 | 24.70 | 1.27M | 2,343,811 | — | ↗ |
| 2021-03-25 | GORDON CARL L | Director | S-Sale | D | Common Stock | 51,523 | 24.70 | 1.27M | 2,343,811 | — | ↗ |
| 2021-03-24 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 32,959 | 24.80 | 817.4K | 2,395,334 | — | ↗ |
| 2021-03-24 | GORDON CARL L | Director | S-Sale | D | Common Stock | 32,959 | 24.80 | 817.4K | 2,395,334 | — | ↗ |
| 2021-03-23 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 3,992 | 24.32 | 97.1K | 2,428,293 | — | ↗ |
| 2021-03-23 | GORDON CARL L | Director | S-Sale | D | Common Stock | 3,992 | 24.32 | 97.1K | 2,428,293 | — | ↗ |
| 2021-03-22 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 7,673 | 26.47 | 203.1K | 2,432,285 | — | ↗ |
| 2021-03-22 | GORDON CARL L | Director | S-Sale | D | Common Stock | 7,673 | 26.47 | 203.1K | 2,432,285 | — | ↗ |
| 2021-03-19 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 21,275 | 26.47 | 563.1K | 2,439,958 | — | ↗ |
| 2021-03-19 | GORDON CARL L | Director | S-Sale | D | Common Stock | 21,275 | 26.47 | 563.1K | 2,439,958 | — | ↗ |
| 2021-03-18 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 6,059 | 28.03 | 169.8K | 2,461,233 | — | ↗ |
| 2021-03-18 | GORDON CARL L | Director | S-Sale | D | Common Stock | 6,059 | 28.03 | 169.8K | 2,461,233 | — | ↗ |
| 2021-03-17 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 18,790 | 28.43 | 534.2K | 2,467,292 | — | ↗ |
| 2021-03-17 | GORDON CARL L | Director | S-Sale | D | Common Stock | 18,790 | 28.43 | 534.2K | 2,467,292 | — | ↗ |
| 2021-03-16 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 41,353 | 27.72 | 1.15M | 2,486,082 | — | ↗ |
| 2021-03-16 | GORDON CARL L | Director | S-Sale | D | Common Stock | 41,353 | 27.72 | 1.15M | 2,486,082 | — | ↗ |
| 2021-03-15 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 89,210 | 29.14 | 2.60M | 2,527,435 | — | ↗ |
| 2021-03-15 | GORDON CARL L | Director | S-Sale | D | Common Stock | 89,210 | 29.14 | 2.60M | 2,527,435 | — | ↗ |
| 2021-03-12 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 90,521 | 30.29 | 2.74M | 2,616,645 | — | ↗ |
| 2021-03-12 | GORDON CARL L | Director | S-Sale | D | Common Stock | 90,521 | 30.29 | 2.74M | 2,616,645 | — | ↗ |
| 2021-03-11 | ORBIMED ADVISORS LLC | Director | S-Sale | D | Common Stock | 58,551 | 33.04 | 1.93M | 2,707,166 | — | ↗ |
| 2021-03-11 | GORDON CARL L | Director | S-Sale | D | Common Stock | 58,551 | 33.04 | 1.93M | 2,707,166 | — | ↗ |
| 2021-02-01 | Piscitelli Dominic | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 29.83 | 2.68M | 90,000 | — | ↗ |
| 2021-02-01 | Multani Pratik S | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 29.83 | 2.68M | 90,000 | — | ↗ |
| 2021-02-01 | Chacko Jacob | Director / Officer | A-Award | A | Stock Option (right to buy) | 280,000 | 29.83 | 8.35M | 280,000 | — | ↗ |
| 2020-11-04 | Topspin Fund L.P. | 10% Owner | S-Sale | D | Common Stock | 2,268,750 | 0.00 | — | 1,100,446 | — | ↗ |
| 2020-06-09 | Kunkel Lori Anne | Director | A-Award | A | Stock Option (right to buy) | 28,515 | 35.92 | 1.02M | 28,515 | — | ↗ |
| 2020-04-28 | Topspin Fund L.P. | 10% Owner | C-Conversion | D | Series C Preferred Stock | 497,809 | 0.00 | — | 0 | — | ↗ |
| 2020-04-28 | Svennilson Peter | Director / 10% Owner | C-Conversion | A | Common Stock | 416,666 | 0.00 | — | 4,616,666 | — | ↗ |
| 2020-04-28 | SCHELLER RICHARD H | Director | C-Conversion | D | Series A Preferred Stock | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2020-04-28 | ORBIMED ADVISORS LLC | Director / 10% Owner | C-Conversion | A | Common Stock | 236,111 | 0.00 | — | 2,765,717 | — | ↗ |
| 2020-04-28 | Heyman Richard A. | Director | C-Conversion | A | Common Stock | 62,500 | 0.00 | — | 227,500 | — | ↗ |
| 2020-04-28 | GORDON CARL L | Director / 10% Owner | C-Conversion | A | Common Stock | 373,356 | 0.00 | — | 2,529,606 | — | ↗ |
| 2020-04-28 | Chacko Jacob | Director / Officer | C-Conversion | A | Common Stock | 62,500 | 0.00 | — | 62,500 | — | ↗ |
| 2020-04-28 | COLUMN GROUP II, LP | 10% Owner | C-Conversion | A | Common Stock | 416,666 | 0.00 | — | 4,616,666 | — | ↗ |
| 2020-04-24 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 281,250 | 16.00 | 4.50M | 281,250 | — | ↗ |
| 2020-04-24 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 281,250 | 16.00 | 4.50M | 281,250 | — | ↗ |
| 2020-04-23 | Topspin Fund L.P. | 10% Owner | — | D | Series C Preferred Stock | 497,809 | 0.00 | — | 0 | — | ↗ |
| 2020-04-23 | Svennilson Peter | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 75,000 | — | ↗ |
| 2020-04-23 | SCHELLER RICHARD H | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2020-04-23 | Piscitelli Dominic | Officer | — | D | Stock Option (right to buy) | 207,500 | 6.44 | 1.34M | 0 | — | ↗ |
| 2020-04-23 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Series B Preferred Stock | 1,875,000 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
100.36M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 657.5K | — | 826.0K | 3.63M | 434.0K | 15.1K | 5.57M | 80.12% | ↗ |
| 2 | 2025 | Pratik Multani, M.D. Chief Medical Officer | 513.3K | — | 280.8K | 1.23M | 246.5K | 15.1K | 2.28M | 66.05% | ↗ |
| 3 | 2025 | Dominic Piscitelli Chief Financial Officer | 482.9K | — | 280.8K | 1.23M | 231.9K | 15.1K | 2.24M | 67.38% | ↗ |
| 4 | 2024 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 627.3K | — | 776.9K | 3.47M | 396.8K | 14.9K | 5.28M | 80.33% | ↗ |
| 5 | 2024 | Pratik Multani, M.D. Chief Medical Officer | 493.6K | — | 274.2K | 1.22M | 227.1K | 14.9K | 2.23M | 67.06% | ↗ |
| 6 | 2024 | Dominic Piscitelli Chief Financial Officer | 458.1K | — | 274.2K | 1.22M | 210.8K | 15.3K | 2.18M | 68.64% | ↗ |
| 7 | 2023 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 596.1K | — | 396.0K | 1.80M | 350.2K | 14.7K | 3.15M | 69.52% | ↗ |
| 8 | 2023 | Pratik Multani, M.D. Chief Medical Officer | 476.5K | — | 144.0K | 651.1K | 224.0K | 14.7K | 1.51M | 52.64% | ↗ |
| 9 | 2023 | Dominic Piscitelli Chief Financial Officer | 435.6K | — | 144.0K | 651.1K | 204.8K | 14.4K | 1.45M | 54.84% | ↗ |
| 10 | 2022 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 572.1K | — | 474.0K | 2.97M | 336.1K | 13.1K | 4.37M | 78.89% | ↗ |
| 11 | 2022 | Dominic Piscitelli Chief Financial Officer | 418.3K | — | 171.8K | 1.11M | 196.6K | 21.9K | 1.92M | 66.82% | ↗ |
| 12 | 2022 | Pratik Multani, M.D. Chief Medical Officer | 458.3K | — | 171.8K | 1.05M | 215.4K | 13.1K | 1.91M | 64.02% | ↗ |
| 13 | 2021 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 536.3K | — | — | 6.09M | 335.2K | 12.2K | 6.98M | 87.33% | ↗ |
| 14 | 2021 | Pratik Multani, M.D. Chief Medical Officer | 438.4K | — | — | 1.96M | 219.2K | 12.2K | 2.63M | 74.51% | ↗ |
| 15 | 2021 | Dominic Piscitelli Chief Financial Officer | 398.5K | — | — | 1.96M | 199.3K | 12.2K | 2.57M | 76.25% | ↗ |
| 16 | 2020 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 489.2K | — | — | 5.08M | 300.8K | 988.00 | 5.87M | 86.53% | ↗ |
| 17 | 2020 | Pratik Multani, M.D. Chief Medical Officer | 416.7K | — | — | 1.71M | 205.0K | 621.00 | 2.34M | 73.36% | ↗ |
| 18 | 2020 | Dominic Piscitelli Chief Financial Officer | 380.8K | — | — | 1.00M | 187.4K | 606.00 | 1.57M | 63.79% | ↗ |
| 19 | 2019 | Dominic Piscitelli Chief Financial Officer | 115.1K | — | — | 1.08M | 38.3K | 111.00 | 1.24M | 87.58% | ↗ |
| 20 | 2019 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 455.8K | — | — | — | 194.9K | 21.4K | 672.1K | 0.00% | ↗ |
| 21 | 2019 | Pratik Multani, M.D. Chief Medical Officer | 398.3K | — | — | — | 132.4K | 4.4K | 535.2K | 0.00% | ↗ |
| 22 | 2018 | Jacob M. Chacko, M.D. President and Chief Executive Officer | 290.0K | — | — | 1.19M | 92.8K | 57.9K | 1.64M | 73.05% | ↗ |
| 23 | 2018 | Pratik Multani, M.D. Chief Medical Officer | 112.5K | — | — | 324.8K | 27.0K | 25.9K | 490.1K | 66.26% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jacob Chacko | President, Chief Executive Officer & Director | 1M | — |
| Pratik S. Multani | Chief Medical Officer | 774.9K | — |
| Dominic G. Piscitelli | Chief Financial Officer | 729.9K | male |
| Richard A. Heyman | Founder, Independent Chairman & Member of Scientific Advisory Board | 100.0K | — |
| Kevin Brodbeck | Chief Technical Officer | — | — |
| Lori Sickels Friedman | Chief Scientific Officer | — | — |
| Matthew Panuwat | Chief Business Officer | — | male |
| Charles L. Sawyers | Founder & Member of Scientific Advisory Board | — | — |
| Scott W. Lowe | Founder & Member of Scientific Advisory Board | — | — |
| Christian V. Kuhlen | General Counsel | — | — |
| Daniel Iazzetti | Vice President & Head of People | — | male |
| Edna Chow Maneval | Executive Vice President of Clinical Development | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ORIC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
